Healthcare
SAB Biotherapeutics, Inc.(SABSW)
Live Price
Offline$0.0358
+0.00% today
Window Change
-58.38%
Window
May 27, 2026 โ Jun 15, 2026
- Market Cap
- $40.00M
- Revenue Growth
- -100.0%
- EPS Growth
- +106.0%
- Dividend Yield
- 0.0%
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 14 bars ยท May 27, 2026 โ Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
SAB Biotherapeutics, Inc. (SABSW) is a Healthcare stock with a market cap of $40.00M and listed on NASDAQ. The stock last traded around $0.04 and down 58.4% across the available one-year price window (May 27, 2026 โ Jun 15, 2026). Baseline metrics include revenue growth of -100.0%, EPS growth of +106.0%, a dividend yield of 0.0%. What stands out right now is revenue -100.0%, EPS +106.0%, free cash flow -32.0% with operating margin 0.0% and ROIC -30.0%. Valuation is more restrained than many high-expectation growth names at P/E 5.4. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SABSW price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-100.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
P/E
Below sector median
5.4 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 8, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -100.0% and EPS is at +106.0%, with operating margin around 0.0%.
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SABSW
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
SABSW Max Drawdown
-58.38%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for SABSW and SPY.
Company Overview
SAB Biotherapeutics, Inc.
NASDAQ Global Market
SAB Biotherapeutics, Inc., a biopharmaceutical company, develops immunotherapies against infectious diseases, autoimmune diseases, and oncology. It offers SAB-142 anti-thymocyte globulin for Type 1 diabetes; SAB-176 for seasonal influenza; and SAB-301 for Middle East Respiratory Syndrome Coronavirus (MERS-COV). SAB Biotherapeutics, Inc. was incorporated in 2014 and is based in Sioux Falls, South Dakota with an additional office in Cambridge, Massachusetts.
- Leadership
- Samuel J. Reich
- IPO Date
- Oct 25, 2021
- Employees
- 63
- Street Address
- 2100 East 54th Street North
- Mailing
- Sioux Falls, SD, 33140
- Region
- Sioux Falls, SD, US
- Reporting Currency
- USD
- Investor Line
- 605-679-6980
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 5.4
- EV/EBITDA
- 1.8
- Price/Sales
- โ
- Price/Book
- 0.5
Growth
- Revenue
- -100.0%
- EPS
- +106.0%
- Free Cash Flow
- -32.0%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- 15.2%
- ROIC
- -30.0%
Balance Sheet
- Debt/Equity
- 0.04
- Current Ratio
- 9.46
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.